Abstract
Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.
| Original language | English |
|---|---|
| Pages (from-to) | 229-239 |
| Number of pages | 11 |
| Journal | Future Cardiology |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2006 |
Fingerprint
Keywords
- Major adverse cardiac events
- Paclitaxel-eluting stent
- Restenosis
- Revascularization
ASJC Scopus subject areas
- Molecular Medicine
- Cardiology and Cardiovascular Medicine
Cite this
Paclitaxel-eluting stents. / Cosgrave, John; Simon, Corbett; Babic, Rade; Colombo, Antonio.
In: Future Cardiology, Vol. 2, No. 2, 02.2006, p. 229-239.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paclitaxel-eluting stents
AU - Cosgrave, John
AU - Simon, Corbett
AU - Babic, Rade
AU - Colombo, Antonio
PY - 2006/2
Y1 - 2006/2
N2 - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.
AB - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.
KW - Major adverse cardiac events
KW - Paclitaxel-eluting stent
KW - Restenosis
KW - Revascularization
UR - http://www.scopus.com/inward/record.url?scp=33646597258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646597258&partnerID=8YFLogxK
U2 - 10.2217/14796678.2.2.229
DO - 10.2217/14796678.2.2.229
M3 - Article
C2 - 19804079
AN - SCOPUS:33646597258
VL - 2
SP - 229
EP - 239
JO - Future Cardiology
JF - Future Cardiology
SN - 1479-6678
IS - 2
ER -